✦ LIBER ✦

Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention

✍ Scribed by Marc J Schweiger; Hameem U Changezi; Deborah Naglieri-Prescod; James R Cook

Book ID: 117321529
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 535 KB
Volume: 25
Category: Article
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(03)90029-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence and time course of thrombocyto

Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention

✍ Ibrahim E. Fahdi; Jorge F. Saucedo; Thomas Hennebry; Mohammad Ghani; Saihari Sad 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Comparison of abciximab with “high-dose”

Comparison of abciximab with “high-dose” tirofiban in patients undergoing percutaneous coronary intervention

✍ Athula P. Gunasekara; Darren L. Walters; Con N. Aroney 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Comparison of efficacy and safety of nat

Comparison of efficacy and safety of native eptifibatide vs. tirofiban in patients with acute coronary syndrome undergoing percutaneous coronary intervention

✍ Jianjin Tang; Liansheng Wang; Hui Wang; Mingwei Wang; Kejiang Cao; Zhijian Yang 📂 Article 📅 2008 🏛 Chinese Electronic Periodical Services 🌐 English ⚖ 132 KB

Safety of abciximab in patients with chr

Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions

✍ Patricia J.M Best; Ryan Lennon; Bernard J Gersh; Henry H Ting; Charanjit S Rihal 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Time course, magnitude, and consistency

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

✍ Dean J Kereiakes; Thomas M Broderick; Eli M Roth; David Whang; Thomas Shimshak; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 454 KB

A comparison of total hospital costs for

A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban

✍ Patrick L. McCollam; Maureen J. Lage; Mohan Bala 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

## Abstract The purpose of this study was to examine the total hospital costs associated with the receipt of abciximab versus tirofiban for percutaneous coronary intervention (PCI) patients. Hospital billing data for patients with a primary procedure of PCI was examined for the period of July 1998